Pulmonary-Allergy Drugs Advisory Committee; Cancellation

---
identifier: "/us/fr/2019-06389"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Pulmonary-Allergy Drugs Advisory Committee; Cancellation"
title_number: 0
title_name: "Federal Register"
section_number: "2019-06389"
section_name: "Pulmonary-Allergy Drugs Advisory Committee; Cancellation"
positive_law: false
currency: "2019-04-02"
last_updated: "2019-04-02"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2019-06389"
document_type: "notice"
publication_date: "2019-04-02"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "84 FR 12626"
fr_volume: 84
docket_ids:
  - "Docket No. FDA-2019-N-0218"
fr_action: "Notice."
---


#  Pulmonary-Allergy Drugs Advisory Committee; Cancellation

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice.

**SUMMARY:**

The meeting of the Pulmonary-Allergy Drugs Advisory Committee scheduled for March 27, 2019, has been cancelled. This meeting was announced in the *Federal Register* of January 31, 2019. This meeting has been cancelled due to new information regarding the application. The Agency intends to continue evaluating the application and, as needed, will announce future meeting dates in the *Federal Register* .

**FOR FURTHER INFORMATION CONTACT:**

Cindy Chee, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax: 301-847-8533, email: *[email protected],* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting, which was announced in the *Federal Register* of January 31, 2019 (84 FR 748).

Dated: March 28, 2019.

Lowell J. Schiller,

Acting Associate Commissioner for Policy.